Table 4

Site-specific and overall cancer risk for children and adults with PID

Cancer siteOESIR (95% CI)
Children (< 16 y; n = 613)    
    All malignant neoplasms† 4 0.64 6.21 (1.69-15.9)* 
    NHL 2 0.20 9.78 (1.18-35.3)* 
    Leukemia 1 0.04 24.6 (0.62-137) 
Adults (≥ 16 y; n = 850)    
    All malignant neoplasms† 54 35.6 1.52 (1.14-1.98)* 
    NHL 14 1.61 8.70 (4.76-14.6)* 
    Leukemia 3 0.71 4.26 (0.88-12.4) 
Cancer siteOESIR (95% CI)
Children (< 16 y; n = 613)    
    All malignant neoplasms† 4 0.64 6.21 (1.69-15.9)* 
    NHL 2 0.20 9.78 (1.18-35.3)* 
    Leukemia 1 0.04 24.6 (0.62-137) 
Adults (≥ 16 y; n = 850)    
    All malignant neoplasms† 54 35.6 1.52 (1.14-1.98)* 
    NHL 14 1.61 8.70 (4.76-14.6)* 
    Leukemia 3 0.71 4.26 (0.88-12.4) 

95% CI indicates 95% confidence interval; E, expected number of cases; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.

*

Statistical significance.

†

C00-C96, excluding C44.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal